Overexpression of CXCR4 synergizes with LL-37 in the metastasis of breast cancer cells
- PMID: 30251699
- DOI: 10.1016/j.bbadis.2018.09.008
Overexpression of CXCR4 synergizes with LL-37 in the metastasis of breast cancer cells
Abstract
Chemokine receptor CXCR4 was involved in the progression of breast cancer to a metastatic phenotype, leading to the major cause of death in patients. A more in-depth understanding of signaling mechanism underlying CXCR4 is critical to develop effective therapies toward metastasis. Recently, the role of antimicrobial peptide LL-37 in contributing to the metastasis of breast cancer cells was observed. Clinical analysis of data herein demonstrated for the first time that overexpression of LL-37 and CXCR4 co-existed in human primary breast tumors with lymph node metastases. Further study disclosed that forced expression of CXCR4 led to the enhancement of pro-migratory signaling and migration rate induced by LL-37 in breast cancer cells. Moreover, LL-37 affected tumor microenvironment including induction of migration of mesenchymal stem cells and CXCR4-dependent capillary-like tubule formation. Functional analysis showed that LL-37 induced the internalization of CXCR4 through approaching Glu268, the residue of CXCR4, independent of the binding pocket (Asp171, Asp262, and Glu288) for CXCR4 inhibitor AMD3100, signifying that LL-37 is a distinct agonist of CXCR4. These results suggest the reciprocal roles of LL-37 and CXCR4 in promoting breast cancer cell migration and provide new insight into the design of CXCR4 inhibitor for intervention of metastatic breast cancer.
Keywords: Breast cancer; CXCR4; Epithelial-mesenchymal transition; LL-37; Metastasis.
Copyright © 2018. Published by Elsevier B.V.
Similar articles
-
Transcription factor RUNX2 up-regulates chemokine receptor CXCR4 to promote invasive and metastatic potentials of human gastric cancer.Oncotarget. 2016 Apr 12;7(15):20999-1012. doi: 10.18632/oncotarget.8236. Oncotarget. 2016. PMID: 27007162 Free PMC article.
-
Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.Exp Cell Res. 2011 Nov 1;317(18):2573-81. doi: 10.1016/j.yexcr.2011.08.016. Epub 2011 Aug 30. Exp Cell Res. 2011. PMID: 21906588 Free PMC article.
-
A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity.Oncotarget. 2014 Feb 15;5(3):599-612. doi: 10.18632/oncotarget.1169. Oncotarget. 2014. PMID: 24583601 Free PMC article.
-
Modulators of CXCR4 and CXCR7/ACKR3 Function.Mol Pharmacol. 2019 Dec;96(6):737-752. doi: 10.1124/mol.119.117663. Epub 2019 Sep 23. Mol Pharmacol. 2019. PMID: 31548340 Review.
-
Chemokines and chemokine receptors: new insights into cancer-related inflammation.Trends Mol Med. 2010 Mar;16(3):133-44. doi: 10.1016/j.molmed.2010.01.003. Epub 2010 Feb 15. Trends Mol Med. 2010. PMID: 20163989 Free PMC article. Review.
Cited by
-
A methylation-based mRNA signature predicts survival in patients with gastric cancer.Cancer Cell Int. 2020 Jul 6;20:284. doi: 10.1186/s12935-020-01374-w. eCollection 2020. Cancer Cell Int. 2020. PMID: 32647495 Free PMC article.
-
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.Molecules. 2022 Aug 5;27(15):4988. doi: 10.3390/molecules27154988. Molecules. 2022. PMID: 35956937 Free PMC article.
-
Cathelicidin LL-37 promotes EMT, migration and metastasis of hepatocellular carcinoma cells in vitro and mouse model.Cell Adh Migr. 2023 Dec;17(1):20-34. doi: 10.1080/19336918.2023.2168231. Cell Adh Migr. 2023. PMID: 36656313 Free PMC article.
-
Identifying and Assessing Putative Allosteric Sites and Modulators for CXCR4 Predicted through Network Modeling and Site Identification by Ligand Competitive Saturation.J Phys Chem B. 2024 May 30;128(21):5157-5174. doi: 10.1021/acs.jpcb.4c00925. Epub 2024 Apr 22. J Phys Chem B. 2024. PMID: 38647430 Free PMC article.
-
Endogenous Peptide Inhibitors of HIV Entry.Adv Exp Med Biol. 2022;1366:65-85. doi: 10.1007/978-981-16-8702-0_5. Adv Exp Med Biol. 2022. PMID: 35412135
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials